Ono Pharmaceutical (OTCMKTS:OPHLF) Announces Quarterly Earnings Results, Beats Estimates By $0.15 EPS

Ono Pharmaceutical (OTCMKTS:OPHLF) posted its quarterly earnings data on Friday. The company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.25 by $0.15, Zacks reports. Ono Pharmaceutical had a net margin of 13.51% and a return on equity of 8.55%.

Ono Pharmaceutical Price Performance

OPHLF remained flat at $14.61 on Friday. Ono Pharmaceutical has a 1 year low of $10.27 and a 1 year high of $18.67. The stock has a market cap of $6.87 billion, a PE ratio of 14.76 and a beta of 0.34. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.56 and a current ratio of 3.02. The company’s 50 day moving average is $14.33 and its 200 day moving average is $14.77.

Analyst Ratings Changes

Separately, Zacks Research raised shares of Ono Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, Ono Pharmaceutical has an average rating of “Strong Buy”.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research?based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.